MY133125A - Novel dihydroxyhexanoic acid derivatives - Google Patents

Novel dihydroxyhexanoic acid derivatives

Info

Publication number
MY133125A
MY133125A MYPI99000363A MYPI9900363A MY133125A MY 133125 A MY133125 A MY 133125A MY PI99000363 A MYPI99000363 A MY PI99000363A MY PI9900363 A MYPI9900363 A MY PI9900363A MY 133125 A MY133125 A MY 133125A
Authority
MY
Malaysia
Prior art keywords
acid derivatives
dihydroxyhexanoic acid
novel
novel dihydroxyhexanoic
greneral
Prior art date
Application number
MYPI99000363A
Other languages
English (en)
Inventor
John Charles Kath
Matthew Frank Brown
Christopher Stanley Poss
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MY133125A publication Critical patent/MY133125A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
MYPI99000363A 1998-02-05 1999-02-03 Novel dihydroxyhexanoic acid derivatives MY133125A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7380198P 1998-02-05 1998-02-05

Publications (1)

Publication Number Publication Date
MY133125A true MY133125A (en) 2007-10-31

Family

ID=22115885

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI99000363A MY133125A (en) 1998-02-05 1999-02-03 Novel dihydroxyhexanoic acid derivatives

Country Status (36)

Country Link
EP (1) EP1051405B1 (enExample)
JP (1) JP3693916B2 (enExample)
KR (1) KR100385529B1 (enExample)
CN (1) CN1177834C (enExample)
AP (1) AP992A (enExample)
AR (1) AR016175A1 (enExample)
AT (1) ATE337307T1 (enExample)
AU (1) AU752407B2 (enExample)
BG (1) BG104726A (enExample)
BR (1) BR9907655A (enExample)
CA (1) CA2320388C (enExample)
DE (1) DE69932920T2 (enExample)
DZ (1) DZ2717A1 (enExample)
EA (1) EA003137B1 (enExample)
ES (1) ES2268847T3 (enExample)
GT (1) GT199900011A (enExample)
HR (1) HRP20000529B1 (enExample)
HU (1) HUP0100832A3 (enExample)
IL (1) IL137330A0 (enExample)
IS (1) IS5562A (enExample)
MA (1) MA26603A1 (enExample)
MY (1) MY133125A (enExample)
NO (1) NO20003965D0 (enExample)
NZ (1) NZ505724A (enExample)
OA (1) OA11448A (enExample)
PA (1) PA8467301A1 (enExample)
PE (1) PE20000243A1 (enExample)
PL (1) PL342817A1 (enExample)
SK (1) SK11262000A3 (enExample)
TN (1) TNSN99013A1 (enExample)
TR (1) TR200002248T2 (enExample)
TW (1) TW470744B (enExample)
UA (1) UA57824C2 (enExample)
WO (1) WO1999040061A2 (enExample)
YU (1) YU47100A (enExample)
ZA (1) ZA99873B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360672A1 (en) * 1999-01-29 2000-08-03 Wayne W. Hancock Methods for preventing graft rejection and ischemia-reperfusion injury
PL205059B1 (pl) * 1999-08-20 2010-03-31 Dow Agrosciences Llc Heterocykliczny amid aromatyczny, jego kompozycja grzybobójcza oraz sposób zwalczania lub zapobiegania zakażeniom grzybami
EA200401099A1 (ru) 2000-02-04 2005-02-24 Пфайзер Продактс Инк. Производные гетероциклического амида
EP1498417A1 (en) * 2000-02-04 2005-01-19 Pfizer Products Inc. Heterocyclic amide derivatives
US6740636B2 (en) 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
US6746856B2 (en) 2000-08-09 2004-06-08 Pfizer Inc. Microbial conversion of bicyclic heteroaromatic compounds
OA12625A (en) 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
EP1506182A1 (en) * 2002-05-14 2005-02-16 Pfizer Products Inc. Methods for the manufacture of dihydro-furan-2-one derivatives
BR0309930A (pt) 2002-05-14 2005-02-09 Pfizer Prod Inc Derivados do ácido dihidroxihexanóico, seus intermediários e métodos de produção
WO2004014875A1 (en) * 2002-08-12 2004-02-19 Pfizer Products Inc. Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide
EP1530457B1 (en) 2002-08-12 2009-09-09 Bend Research, Inc. Pharmaceutical compositions of drugs in semi-ordered form and polymers
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923864A (en) * 1987-12-15 1990-05-08 Pfizer Inc. Certain heterocyclic-hexanamides useful for treating hypertension
DK0708085T3 (da) * 1994-10-19 2002-11-11 Novartis Ag Antivirale ethere af aspartatproteasesubstrat-isostere
DE19708106A1 (de) * 1997-02-28 1998-09-03 Bosch Gmbh Robert Einrichtung und Verfahren zur Information über Verkehrsstörungen

Also Published As

Publication number Publication date
MA26603A1 (fr) 2004-12-20
WO1999040061A3 (en) 1999-10-21
NO20003965L (enExample) 2000-10-03
DZ2717A1 (fr) 2003-09-01
HUP0100832A2 (hu) 2002-02-28
JP3693916B2 (ja) 2005-09-14
ATE337307T1 (de) 2006-09-15
YU47100A (sh) 2002-11-15
BR9907655A (pt) 2000-10-24
AP9901457A0 (en) 1999-03-31
TNSN99013A1 (fr) 2005-11-10
AR016175A1 (es) 2001-06-20
SK11262000A3 (sk) 2001-01-18
ES2268847T3 (es) 2007-03-16
HUP0100832A3 (en) 2002-03-28
ZA99873B (en) 2000-08-04
DE69932920T2 (de) 2007-02-08
EA003137B1 (ru) 2003-02-27
DE69932920D1 (de) 2006-10-05
HRP20000529A2 (en) 2001-08-31
CN1177834C (zh) 2004-12-01
EP1051405A2 (en) 2000-11-15
CN1290255A (zh) 2001-04-04
CA2320388A1 (en) 1999-08-12
JP2002502839A (ja) 2002-01-29
PL342817A1 (en) 2001-07-02
AU752407B2 (en) 2002-09-19
KR100385529B1 (ko) 2003-05-27
IL137330A0 (en) 2001-07-24
KR20010040684A (ko) 2001-05-15
HRP20000529B1 (en) 2004-12-31
PA8467301A1 (es) 2000-05-24
IS5562A (is) 2000-07-14
GT199900011A (es) 2000-07-20
CA2320388C (en) 2005-05-03
TW470744B (en) 2002-01-01
NZ505724A (en) 2003-02-28
WO1999040061A2 (en) 1999-08-12
PE20000243A1 (es) 2000-04-07
NO20003965D0 (no) 2000-08-04
UA57824C2 (uk) 2003-07-15
EA200000741A1 (ru) 2001-02-26
AP992A (en) 2001-08-06
OA11448A (en) 2003-11-18
HK1034969A1 (en) 2001-11-09
EP1051405B1 (en) 2006-08-23
AU1778999A (en) 1999-08-23
TR200002248T2 (tr) 2000-12-21
BG104726A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
MY121294A (en) Novel hexanoic acid derivatives.
MY133125A (en) Novel dihydroxyhexanoic acid derivatives
IL112495A0 (en) Phenylacetic acid derivatives, their preparation and compositions containing them
TW352384B (en) Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
AP2002002637A0 (en) Novel piperazine
ZA988158B (en) Sulfinic acid derivatives and their preparation and use
IL147184A0 (en) Substituted benzimidazole
ZA9710796B (en) Oxyiminopregnanecarbolactones.
PL354528A1 (en) Substituted indoles for modulating nfkb activity
MY111201A (en) New imidazopyridines
MX9600487A (es) Composiciones topicamente administrables que contienen derivados de acido 3-benzoilfenilacetico para el tratamiento de trastornos inflamatorios oftalmicos.
MX9709238A (es) Formulaciones farmaceuticas y de dieta para la profilaxis y tratamiento de trastornos gastrointestinales.
IL137508A0 (en) Glucocorticoid-selective anti-inflammatory agents
MY109722A (en) Azaoxindole derivatives.
TR199802060T2 (xx) Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�.
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
IT1285770B1 (it) Composti corticoidei
MY115211A (en) Novel amino acid derivatives, their preparation and use
GR3034575T3 (en) Steroid nitrite ester derivatives useful as anti-inflammatory drugs
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
IL150125A0 (en) Novel compounds
CA2227711A1 (en) Thioctic acid metabolites and methods of use thereof
GR3031602T3 (en) Novel 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase.
BG102814A (en) New derivatives of carboxylic acid, their preparation and application
BG100248A (bg) Инхибитори на скваленсинтетаза